HCW Biologics (NASDAQ:HCWB) Posts Earnings Results

HCW Biologics (NASDAQ:HCWB) posted its earnings results on Friday. The company reported ($0.08) EPS for the quarter, Zacks reports. HCW Biologics had a negative return on equity of 2,516.84% and a negative net margin of 1,067.82%.

HCW Biologics Stock Performance

Shares of NASDAQ HCWB opened at $0.30 on Friday. HCW Biologics has a 1 year low of $0.21 and a 1 year high of $2.52. The stock’s 50-day simple moving average is $0.36 and its 200-day simple moving average is $0.44. The firm has a market cap of $13.36 million, a price-to-earnings ratio of -0.30 and a beta of 0.71.

About HCW Biologics

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.